Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Non-Current Liabilities (2021 - 2024)

Aligos Therapeutics (ALGS) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $72.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Non-Current Liabilities rose 162.24% year-over-year to $72.4 million, compared with a TTM value of $72.4 million through Dec 2024, up 162.24%, and an annual FY2024 reading of $72.4 million, up 162.24% over the prior year.
  • Other Non-Current Liabilities was $72.4 million for Q4 2024 at Aligos Therapeutics, up from $11.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $72.4 million in Q4 2024 and bottomed at $133000.0 in Q4 2021.
  • Average Other Non-Current Liabilities over 4 years is $13.9 million, with a median of $267000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities plummeted 50.19% in 2022, then surged 162.24% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $133000.0 in 2021, then changed by 0.0% to $133000.0 in 2022, then soared by 20648.87% to $27.6 million in 2023, then skyrocketed by 162.24% to $72.4 million in 2024.
  • Business Quant data shows Other Non-Current Liabilities for ALGS at $72.4 million in Q4 2024, $11.6 million in Q3 2024, and $11.5 million in Q2 2024.